Cardiovascular Drugs Practice Questions

Q: Which beta-blocker lacks local anesthetic effect?

Atenolol. **Explanation:** The "local anesthetic effect" of beta-blockers is also known as **Membrane Stabilizing Activity (MSA)**. This property is due to the blockade of voltage-gated sodium channels, similar to the mechanism of lidocaine. Drugs with high MSA can cause decreased corneal sensitivity (when used topically) and are more toxic in overdose due to cardiac conduction delays. **1. Why Atenolol is correct:** Atenolol is a **hydrophilic (water-soluble)**, cardioselective beta-1 blocker. It completely lacks membrane stabilizing activity (MSA). Because it is hydrophilic, it also has poor CNS penetration, leading to fewer side effects like nightmares or depression. **2. Why the other options are incorrect:** * **Metoprolol:** This is a cardioselective beta-blocker that possesses **weak but present** membrane stabilizing activity. * **Pindolol:** This is a non-selective beta-blocker with **significant** membrane stabilizing activity. It is also notable for having Intrinsic Sympathomimetic Activity (ISA). **High-Yield Clinical Pearls for NEET-PG:** * **Strongest MSA:** **Propranolol** has the highest membrane stabilizing activity (making it dangerous in overdose due to QRS widening). * **Beta-blockers with MSA:** Propranolol, Pindolol, Acebutolol, Metoprolol, and Labetalol. * **Beta-blockers WITHOUT MSA:** **Atenolol**, Sotalol, Timolol, and Nadolol. * **Clinical Significance:** Beta-blockers with MSA (like Propranolol) should never be used as eye drops for glaucoma because they would anesthetize the cornea, leading to a loss of the protective blink reflex and potential corneal ulceration. **Timolol** is preferred in glaucoma because it lacks MSA.

Q: What is the mechanism of action of digitalis?

Decrease in heart rate with decrease in oxygen consumption. **Mechanism of Action of Digitalis (Digoxin)** The therapeutic effect of digitalis in heart failure is unique because it increases cardiac output while simultaneously reducing the workload of the heart. **Why Option D is Correct:** 1. **Decrease in Heart Rate:** Digitalis exerts a **vagomimetic effect** (parasympathetic activation) and slows conduction through the AV node. This increases the diastolic filling time, leading to a decrease in heart rate (negative chronotropy). 2. **Decrease in Oxygen Consumption ($MVO_2$):** Although digitalis is a positive inotrope (it increases force of contraction by inhibiting the $Na^+/K^+$ ATPase pump), in a failing heart, it significantly **reduces ventricular wall tension** and heart size (Laplace’s Law). The reduction in heart rate and wall tension outweighs the energy cost of increased contractility, leading to a net **decrease** in myocardial oxygen demand. **Analysis of Incorrect Options:** * **Options A & B:** These are incorrect because digitalis is a **negative chronotrope**. It decreases heart rate, making it useful in controlling ventricular rate in atrial fibrillation. * **Option C:** While digitalis does decrease heart rate, it does not increase oxygen consumption in a failing heart. Drugs that increase both contractility and oxygen consumption (like Dobutamine) can worsen ischemia, whereas digitalis is more "oxygen-efficient" in the context of heart failure. **NEET-PG High-Yield Pearls:** * **Molecular Target:** Reversible inhibition of the **$Na^+/K^+$ ATPase pump** on the sarcolemma. * **ECG Changes:** Characterized by the **"Reverse Tick"** or "Sagging" ST-segment depression (Salvador Dali mustache sign). * **Electrolyte Interaction:** **Hypokalemia** predisposes to digitalis toxicity because $K^+$ and Digoxin compete for the same binding site on the ATPase pump. * **Antidote:** Digoxin-specific antibody fragments (**DigiFab**).

Q: A premature infant is born with a patent ductus arteriosus. Its closure can be stimulated by administration of:

Prostaglandin inhibitors. **Explanation:** The patency of the **Ductus Arteriosus (DA)** in utero is actively maintained by high levels of circulating **Prostaglandins (specifically PGE2)**, which are produced by the placenta and the ductal tissue itself. PGE2 acts on EP4 receptors to cause vasodilation of the ductal smooth muscle. **Why the correct answer is right:** At birth, PGE2 levels normally fall, leading to functional closure of the ductus. In premature infants, if the ductus remains patent (PDA), pharmacological closure can be achieved by administering **Prostaglandin Inhibitors**, specifically non-selective **NSAIDs** like **Indomethacin** or **Ibuprofen**. These drugs inhibit the enzyme Cyclooxygenase (COX), thereby decreasing PGE2 synthesis and allowing the ductus to constrict and close. **Why the incorrect options are wrong:** * **A. Prostaglandin analogue:** Administering PGE1 (Alprostadil) would keep the ductus *open*. This is clinically indicated in cyanotic heart diseases (e.g., Transposition of Great Arteries) where a PDA is life-saving. * **B & C. Estrogen/Anti-estrogen:** These hormonal compounds have no direct physiological role in the acute contraction or relaxation of the ductus arteriosus smooth muscle. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** While Indomethacin was the traditional gold standard, **Ibuprofen** is often preferred now due to a lower risk of renal side effects and necrotizing enterocolitis (NEC). * **Alternative:** Recent studies suggest **Paracetamol (Acetaminophen)** is also effective for PDA closure with fewer side effects. * **Mnemonic:** To **K**eep the ductus open, give PGE (Alprostadil). To **C**lose it, give **C**OX inhibitors (Indomethacin).

Q: Oral sacubitril is approved for the treatment of which condition?

Congestive cardiac failure. **Explanation:** **Sacubitril** is a first-in-class **Neprilysin inhibitor**. It is primarily used in combination with Valsartan (an Angiotensin Receptor Blocker) as an **ARNI** (Angiotensin Receptor-Neprilysin Inhibitor) for the management of **Congestive Cardiac Failure (CCF)**, specifically Heart Failure with reduced Ejection Fraction (HFrEF). * **Mechanism of Action:** Neprilysin is an enzyme responsible for the degradation of beneficial endogenous vasoactive peptides, such as **Atrial Natriuretic Peptide (ANP)** and **B-type Natriuretic Peptide (BNP)**. By inhibiting neprilysin, sacubitril increases the levels of these peptides, leading to vasodilation, natriuresis (sodium excretion), and diuresis, while reducing sympathetic tone and cardiac fibrosis. * **Why Valsartan is added:** Neprilysin also degrades Angiotensin II. Therefore, inhibiting neprilysin alone would increase Angiotensin II levels. Adding Valsartan counteracts this effect, providing a synergistic benefit in heart failure patients. **Analysis of Incorrect Options:** * **B. IBS with diarrhea:** Sacubitril has no role here. Eluxadoline or Alosetron are drugs used in IBS-D. * **C. Unstable Angina:** Treatment involves antiplatelets, anticoagulants, and nitrates. Sacubitril is not indicated for acute coronary syndromes. * **D. Vitamin K deficiency:** This is managed with Vitamin K1 (Phytonadione) supplementation. **High-Yield Clinical Pearls for NEET-PG:** * **PARADIGM-HF Trial:** The landmark study that established ARNI superiority over Enalapril in reducing mortality in HFrEF. * **Washout Period:** When switching from an ACE inhibitor to Sacubitril/Valsartan, a **36-hour washout period** is mandatory to prevent the risk of **angioedema** (as both drugs increase bradykinin). * **Contraindication:** Do not use in patients with a history of angioedema related to previous ACEI/ARB therapy.

Q: Which antihypertensive medication is safe to use in patients with renal disease?

Amlodipine. **Explanation:** **Amlodipine** is a long-acting Dihydropyridine Calcium Channel Blocker (CCB). It is considered safe and often preferred in patients with renal disease because it is primarily metabolized by the **liver** and does not require dose adjustment in renal impairment. Furthermore, CCBs do not adversely affect the Glomerular Filtration Rate (GFR) or electrolyte balance, unlike other antihypertensives. **Analysis of Incorrect Options:** * **Atenolol:** This is a hydrophilic beta-blocker that is primarily excreted unchanged by the **kidneys**. In patients with renal failure, it can accumulate, leading to severe bradycardia and toxicity. (Note: Metoprolol is preferred over Atenolol in renal disease as it is hepatically metabolized). * **Thiazides:** These diuretics lose their efficacy when the GFR falls below **30 mL/min**. In advanced renal disease, they are ineffective as antihypertensives (Loop diuretics like Furosemide are used instead). * **Methyldopa:** While used in pregnancy-induced hypertension, it is not a first-line drug for renal patients. Its metabolites are renally cleared, and it can cause significant sedation and central side effects in patients with uremia. **High-Yield Clinical Pearls for NEET-PG:** 1. **DOC for Hypertensive Diabetic Nephropathy:** ACE inhibitors (e.g., Enalapril) or ARBs (e.g., Losartan) are the drugs of choice due to their **renoprotective** effects (dilating the efferent arteriole), provided serum creatinine is <3 mg/dL. 2. **Safe Beta-blockers in Renal Failure:** Metoprolol, Propranolol, and Labetalol (Hepatic metabolism). 3. **Safe Statins in Renal Failure:** Atorvastatin (does not require dose adjustment). 4. **Avoid in Bilateral Renal Artery Stenosis:** ACE inhibitors/ARBs, as they can precipitate acute renal failure.

Q: Regarding lidocaine, all of the following are true EXCEPT:

Dose needs to be altered in renal failure. Lidocaine is a Class IB antiarrhythmic primarily used for ventricular arrhythmias, especially post-myocardial infarction. **Explanation of the Correct Answer (A):** Lidocaine is primarily metabolized by the **liver** via the CYP450 system (specifically CYP1A2 and CYP3A4) into active metabolites like monoethylglycinexylidide (MEGX). Its clearance is highly dependent on hepatic blood flow. Therefore, dose adjustments are crucial in **hepatic failure** or congestive heart failure (due to reduced liver perfusion), but **not in renal failure**, as the kidneys play a negligible role in its primary clearance. **Analysis of Other Options:** * **B. Loading dose is given before infusion:** Lidocaine has a short half-life (approx. 1.5–2 hours). To achieve rapid therapeutic plasma concentrations (1.5–5 µg/mL), a loading dose is mandatory before starting a continuous maintenance infusion. * **C. Little affected by heat and pH:** Lidocaine is a stable compound. Unlike some other local anesthetics, it is relatively resistant to heat (autoclavable) and maintains stability across a reasonable range of pH, though its lipid solubility (and thus onset) is influenced by tissue pH. * **D. It prolongs the refractory period:** While Class IB agents typically shorten the Action Potential Duration (APD) in healthy tissue, they **prolong the Effective Refractory Period (ERP) relative to the APD** in ischemic or depolarized myocardial tissue. This selective action helps suppress ectopic foci. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Lidocaine is no longer the first-line drug for stable VT (Amiodarone is preferred), but it remains an alternative in ACLS protocols. * **Toxicity:** CNS side effects are most common (dizziness, seizures, "Lidocaine crazies"). * **Route:** It undergoes extensive first-pass metabolism; hence, it is **never given orally**.

Q: In an established case of coronary artery disease post myocardial infarction, which of the following drugs will not prolong life expectancy?

Nitrate. **Explanation:** In the management of post-Myocardial Infarction (MI) patients, drugs are categorized into those that provide **symptomatic relief** and those that provide a **mortality benefit** (prolong life expectancy). **Why Nitrates are the correct answer:** Nitrates (e.g., Nitroglycerin, Isosorbide mononitrate) act primarily as venodilators, reducing preload and myocardial oxygen demand. While they are highly effective in relieving anginal pain and managing acute pulmonary edema, they **do not reduce mortality** or prevent future cardiac events in stable post-MI patients. They are purely symptomatic treatments. **Why the other options are incorrect:** * **ACE Inhibitors (e.g., Enalapril, Ramipril):** These prevent "ventricular remodeling" (pathological thinning and dilation of the heart wall) post-MI. They significantly reduce mortality, especially in patients with reduced ejection fraction. * **Statins (e.g., Atorvastatin):** Beyond lowering LDL, statins have "pleiotropic effects" such as stabilizing atherosclerotic plaques and reducing inflammation, which prevents recurrent MI and extends life. * **Aspirin:** As an antiplatelet agent, it prevents thrombus formation on disrupted plaques. It is a cornerstone of secondary prevention that significantly reduces the risk of re-infarction and death. **High-Yield Clinical Pearls for NEET-PG:** 1. **Mortality-reducing drugs post-MI:** Beta-blockers, ACE inhibitors/ARBs, Statins, Aspirin, and Aldosterone antagonists (e.g., Eplerenone). 2. **Nitrate Contraindication:** Never co-administer nitrates with Sildenafil (PDE-5 inhibitors) due to the risk of severe, fatal hypotension. 3. **Nitrate Tolerance:** Continuous use leads to tachyphylaxis; a "nitrate-free interval" of 8–12 hours (usually at night) is required to maintain efficacy.

Q: Which drug can be used to delay the progression of aortic dilatation in Marfan syndrome?

Propranolol. **Explanation:** **Marfan Syndrome** is a genetic connective tissue disorder caused by mutations in the *FBN1* gene, leading to weakened aortic walls. The primary cause of mortality is progressive aortic root dilatation, which leads to dissection or rupture. **Why Propranolol is correct:** Beta-blockers, specifically **Propranolol**, are the traditional first-line therapy to delay aortic dilatation. They work via two mechanisms: 1. **Negative Inotropic Effect:** They decrease the force of myocardial contraction ($dP/dt$), reducing the "hammering" effect of blood against the aortic root. 2. **Negative Chronotropic Effect:** By lowering the heart rate, they reduce the frequency of pulsatile stress on the weakened connective tissue. **Why the other options are incorrect:** * **Vitamin E:** An antioxidant that has no proven clinical benefit in preventing structural vascular changes in Marfan syndrome. * **ACE Inhibitors:** While they reduce afterload, they are not the primary choice for Marfan-related dilatation. However, **Losartan (an ARB)** is a significant alternative as it inhibits TGF-$\beta$ signaling, which is overactive in Marfan syndrome. * **Idebenone:** A synthetic analog of Coenzyme Q10 used primarily in Leber’s Hereditary Optic Neuropathy (LHON) and Friedreich's Ataxia; it has no role in aortic pathology. **High-Yield Clinical Pearls for NEET-PG:** * **First-line drugs:** Beta-blockers (Propranolol/Atenolol). * **Alternative/Adjunct:** Losartan (ARB) is increasingly used because it specifically targets the TGF-$\beta$ pathophysiology. * **Monitoring:** Annual echocardiography is mandatory to monitor aortic root diameter. * **Surgery:** Prophylactic aortic root replacement is indicated when the diameter exceeds **5.0 cm** (or 4.5 cm if there is a family history of dissection).

Q: Which of the following causes increased renin on prolonged use?

Enalapril. ### Explanation The correct answer is **Enalapril**. #### 1. Why Enalapril is Correct Enalapril is an **ACE Inhibitor (ACEi)**. The secretion of renin from the juxtaglomerular (JG) cells is regulated by a **negative feedback loop** mediated by Angiotensin II [2]. * **Mechanism:** ACE inhibitors block the conversion of Angiotensin I to Angiotensin II [1]. * **Result:** The loss of negative feedback by Angiotensin II causes the JG cells to compensate by increasing the production and release of **Renin** [2]. Therefore, all ACE inhibitors and Angiotensin Receptor Blockers (ARBs) lead to a reactive increase in plasma renin levels [1]. #### 2. Why Other Options are Incorrect * **Clonidine & Methyldopa (Option A & C):** These are **centrally acting alpha-2 agonists**. They decrease sympathetic outflow from the vasomotor center. Since renin release is stimulated by sympathetic activity (via $\beta_1$ receptors), these drugs **decrease** renin levels [3]. * **Beta-blockers (Option D):** Renin release is primarily mediated by **$\beta_1$ receptors** on the JG apparatus. Beta-blockers (like Propranolol or Atenolol) directly inhibit this mechanism, leading to a **decrease** in plasma renin levels [3]. #### 3. High-Yield Clinical Pearls for NEET-PG * **Renin Levels:** Increased by ACEis, ARBs, Diuretics (due to volume depletion), and Direct Vasodilators (Hydralazine) [1, 5]. Decreased by Beta-blockers, Clonidine, and NSAIDs (via prostaglandin inhibition). * **Aliskiren:** It is a **Direct Renin Inhibitor**. While it increases the *concentration* of renin (due to loss of feedback), it decreases **Plasma Renin Activity (PRA)**. * **ACEi Side Effects:** Remember the mnemonic **CAPTOPRIL** (Cough, Angioedema, Proteinuria, Taste changes, Orthostatic hypotension, Pregnancy contraindication, Renal artery stenosis contraindication, Increased potassium/Hyperkalemia, Leukopenia).

Q: Gemfibrozil is:

PPAR-alpha activator. **Explanation:** **Gemfibrozil** belongs to the **Fibrate** class of hypolipidemic drugs. Its primary mechanism of action is the activation of **Peroxisome Proliferator-Activated Receptor-alpha (PPAR-α)**, a nuclear receptor. 1. **Why Option B is Correct:** Activation of PPAR-α leads to increased transcription of genes involved in lipid metabolism. This results in: * **Increased Lipoprotein Lipase (LPL) activity:** Enhancing the clearance of triglyceride-rich lipoproteins (VLDL and chylomicrons). * **Increased Apo A-I and Apo A-II synthesis:** Leading to a rise in HDL ("good") cholesterol levels. * **Decreased Apo C-III synthesis:** (Apo C-III normally inhibits LPL), further facilitating triglyceride breakdown. 2. **Why Other Options are Incorrect:** * **Option A & C:** **HMG-CoA Reductase inhibitors** (Statins) are the drugs that inhibit the rate-limiting step of cholesterol synthesis. * **Option D:** **Ezetimibe** is the drug that specifically inhibits cholesterol absorption by targeting the NPC1L1 transporter in the small intestine. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Fibrates are the first-line treatment for **Severe Hypertriglyceridemia** (TG >500 mg/dL) to prevent acute pancreatitis. * **Adverse Effects:** Myopathy and gallstones (cholelithiasis) due to increased biliary cholesterol excretion. * **Drug Interaction:** Gemfibrozil inhibits the glucuronidation of **Statins**, significantly increasing the risk of **rhabdomyolysis** when used in combination. (Note: Fenofibrate is preferred over Gemfibrozil if a statin-fibrate combination is necessary).

Question 1

Which beta-blocker lacks local anesthetic effect?

Accepted Answer

Atenolol

Answer

Metoprolol

Answer

Pindolol

Answer

All of the above

Question 2

What is the mechanism of action of digitalis?

Accepted Answer

Decrease in heart rate with decrease in oxygen consumption

Answer

Increase in heart rate with increase in oxygen consumption

Answer

Increase in heart rate without increase in oxygen consumption

Answer

Decrease in heart rate with increase in oxygen consumption

Question 3

A premature infant is born with a patent ductus arteriosus. Its closure can be stimulated by administration of:

Accepted Answer

Prostaglandin inhibitors

Answer

Prostaglandin analogue

Answer

Estrogen

Answer

Anti-estrogen compounds

Question 4

Oral sacubitril is approved for the treatment of which condition?

Accepted Answer

Congestive cardiac failure

Answer

IBS with diarrhea predominance

Answer

Unstable angina

Answer

Vitamin K deficiency

Question 5

Which antihypertensive medication is safe to use in patients with renal disease?

Accepted Answer

Amlodipine

Answer

Atenolol

Answer

Thiazide

Answer

Methyldopa

Question 6

Regarding lidocaine, all of the following are true EXCEPT:

Accepted Answer

Dose needs to be altered in renal failure

Answer

Loading dose is given before infusion

Answer

It is little affected by heat and pH

Answer

It prolongs the refractory period

Question 7

In an established case of coronary artery disease post myocardial infarction, which of the following drugs will not prolong life expectancy?

Accepted Answer

Nitrate

Answer

ACE inhibitors

Answer

Statin

Answer

Aspirin

Question 8

Which drug can be used to delay the progression of aortic dilatation in Marfan syndrome?

Accepted Answer

Propranolol

Answer

Vitamin E

Answer

ACE inhibitor

Answer

Idebenone

Question 9

Which of the following causes increased renin on prolonged use?

Accepted Answer

Enalapril

Answer

Clonidine

Answer

Methyldopa

Answer

beta-blockers

Question 10

Gemfibrozil is:

Accepted Answer

PPAR-alpha activator

Answer

HMG CoA inhibitor

Answer

Inhibits cholesterol synthesis

Answer

Inhibits cholesterol absorption

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?